Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 9/20 | 0.44 |
| ▸ | HTR1B | P28222 | 6/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 3/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100069 | 1.00 | HTR1D (0.44) | HTR1DHTR1BPDK1PDK2PDK3 | |
| SCHEMBL6100571 | 0.89 | GHSR (0.41) | HTR1DHTR1BGHSR | |
| SCHEMBL6101456 | 0.87 | HTR1D (0.41) | HTR1DHTR1BEPHX2NAMPT | |
| SCHEMBL6100449 | 0.81 | HTR1D (0.39) | HTR1DHTR1B | |
| SCHEMBL6102410 | 0.81 | HTR1D (0.66) | HTR1DHTR1BPDK1PDK2PDK3 | |
| SCHEMBL6102457 | 0.78 | HTR1D (0.38) | HTR1DHTR1BGHSR | |
| SCHEMBL6101983 | 0.77 | HTR1D (0.41) | HTR1DHTR1BGHSRNAMPT | |
| SCHEMBL6101995 | 0.71 | HTR1D (0.84) | HTR1DHTR1BGHSRHTR1ATMPRSS2 | |
| SCHEMBL6101028 | 0.70 | HTR1D (0.60) | HTR1DHTR1BGHSRHTR1ASLC6A4 | |
| SCHEMBL6101016 | 0.68 | HTR1D (0.56) | HTR1DHTR1BPDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368337-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1B LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 2005-06-15 | — | — | EP | disclosed |
| US-20040142925-A1 | Piperazine derivatives their preparation and uses in therapy | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142925-A1 | Piperazine derivatives their preparation and uses in therapy | NR3C2, NR2C2, NR3C1 | HTR1D 294/4885HTR1B 204/4885PDK1 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.